Certara (CERT) vs SOPHiA GENETICS SA (SOPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SOPHiA GENETICS SA (SOPH) has outperformed Certara (CERT) over the past year, gaining 71.9% versus a loss of 30.7%. Over five years, SOPH leads with a -55.6% price change compared with -76.3% for CERT. Certara is the larger company by market cap ($1.32 billion vs $617.8 million), about 2.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CERT | SOPH |
|---|---|---|
| Share price | $8.68 | $7.26 |
| Market cap | $1.32B | $617.77M |
| 1-day change | -3.18% | +1.50% |
| YTD return | +1.70% | +53.10% |
| 1-year return | -30.70% | +71.88% |
| 5-year return | -76.32% | -55.59% |
| Forward P/E | 22.31 | — |
| EPS (TTM) | $-0.14 | $-1.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.12 | $8.98 |
| 52-week low | $4.45 | $3.75 |
| Distance from 52-week high | -33.88% | -19.19% |
| Analyst consensus | buy | none |
| Avg. price target upside | -0.63% | +34.35% |
| Average volume | 3.07M | 547.82K |
| Shares outstanding | 152.54M | 85.13M |
| Employees | 1,515 | 415 |
| Sector | Technology | Technology |
| Industry | Computer Software: Prepackaged Software | EDP Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Certara is about 2.1 times larger than SOPHiA GENETICS SA by market value ($1.32B vs $617.77M).
- SOPH has outperformed CERT by 102.6 percentage points over the past year.
About Certara
CERT stock →Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes.
Technology · Computer Software: Prepackaged Software · 1,515 employees
About SOPHiA GENETICS SA
SOPH stock →SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities.
Technology · EDP Services · 415 employees
CERT vs SOPH FAQ
Which is bigger, Certara or SOPHiA GENETICS SA?
Certara (CERT) is larger, with a market capitalization of $1.32B compared with $617.77M for SOPHiA GENETICS SA (SOPH).
Which stock has performed better over the past year, CERT or SOPH?
SOPH returned +71.88% over the past 12 months, compared with -30.70% for CERT (price return, excluding dividends). Past performance does not predict future results.
Are Certara and SOPHiA GENETICS SA in the same industry?
Both are in the Technology sector, but in different industries: Computer Software: Prepackaged Software for Certara and EDP Services for SOPHiA GENETICS SA.